Evaluation of pharmacokinetic and pharmacodynamic parameters following single dose of sitagliptin in healthy Indian males
- 236 Downloads
Sitagliptin, a dipeptidyl peptidase (DPP)-IV inhibitor approved for the treatment of type 2 diabetes, is reported to be more efficacious in Indian patients than non-Indian patient population. The objective of the study was to evaluate pharmacokinetic and pharmacodynamic (PK/PD) parameters of single-dose sitagliptin 100 mg (Januvia) in healthy Indian male participants.
In a randomised, single-dose, open-label, three-treatment, three-period, three-sequence, crossover bioavailability study, 18 healthy male participants received single-dose of sitagliptin under fasted and fed conditions. PK parameters (Cmax, Tmax, AUC0-∞ and t1/2) were determined using Phoenix WinNonlin software. PD parameters [DPP-IV inhibition, active glucagon-like peptide-1 (GLP-1) and insulin] were determined using established methods.
PK parameters expressed in mean (SD) were Cmax 491.7 (135.9) ng/mL; AUC0-∞ 4256.1 (509.9) ng· hr/mL, Tmax 2.9 (1.0) hr and t1/2 10.4 (3.0) hr. The weighted average (WA) plasma DPP-4 inhibition over 24 h was 89.6% and WA of plasma active GLP-1 over 2 h after standardised meal (geometric mean ratio) was 11.1 (9.9) pM/L which is two- to- four fold higher compared to that reported in other populations. The mean average (SD) AUC of plasma insulin over 2 h of standardised meal was 47.9 (24.9) μIU/mL.
Although, there are differences in pharmacokinetic parameters, no clinically meaningful differences were observed with respect to DPP-IV inhibition between Indian and non-Indian population.
KeywordsSitagliptin Pharmacodynamics Pharmacokinetics Incretins DPP-IV inhibitors
The authors thank clinical researchers and participants who participated in this study. We acknowledge Dr. Sai Krishnaveni Chevooru (for editorial support) during the development of the manuscript. Wockhardt Limited (Mumbai, India) funded the study.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
- 2.International Diabetes Federation IDF. (2015) Diabetes atlas 7. http://www.idf.org/about-diabetes/facts-figures. Accessed march 14,2017
- 12.Mushtaq S, Mayee K, Amreen S et al (2014) A study on the current prescribing patterns of dipeptidyl peptidase 4 inhibitors in a multi speciality hospital outpatient setting. Asian J Pharm Clin Res 7:134–136Google Scholar
- 14.Herman G, Stevens C, Van Dyck K et al (2005) Pharmacokinetics and pharmacodynamics of single doses of sitagliptin, an inhibitor of dipeptidyl peptidase-IV, in healthy participants: results from two randomized, double-blind, placebo-controlled studies with single oral doses. Clin Pharmacol Ther 78:675–688CrossRefPubMedGoogle Scholar
- 21.Ramachandran A, Snehalatha C, Mary S, Mukesh B, Bhaskar AD, Vijay V, Indian Diabetes Prevention Programme (IDPP) (2006) Indian diabetes prevention Programme (IDPP): the Indian diabetes prevention programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian-Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia 49:289–297CrossRefPubMedGoogle Scholar
- 22.Knowler W, Barrett-Connor E, Fowler S, Hamman RF, Lachin JM, Walker EA, Nathan DM, Diabetes Prevention Program Research Group (2002) Diabetes prevention program research group. reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393–403CrossRefPubMedGoogle Scholar
- 24.Ramachandran A, Snehalatha C, Mary S, Selvam S, Kumar CKS, Seeli AC, Shetty AS (2009) Pioglitazone does not enhance the effectiveness of lifestyle modification in preventing conversion of impaired glucose tolerance to diabetes in Asian Indians: results of the Indian diabetes prevention Programme-2 (IDPP-2). Diabetologia 52:1019–1026CrossRefPubMedGoogle Scholar
- 27.Rosenstock J, Brazg R, Andryuk P, Lu K, Stein P, Sitagliptin Study 019 Group (2006) Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized double-blind, placebo-controlled, parallel-group study. Clin Ther 28:1556–1568CrossRefPubMedGoogle Scholar
- 28.Hermansen K, Kipnes M, Luo E, Fanurik D, Khatami H, Stein P, Sitagliptin Study 035 Group (2007) Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes Metab 9:733–745CrossRefPubMedGoogle Scholar